



Our Ref.

TEL: (356) 21224071

Your Ref.

FAX: (356) 21242884

DH Circular 203/05

28<sup>th</sup> September 05

To all Medical Officers  
Pharmacists  
Nurses

Monotard<sup>®</sup> and Ultratard<sup>®</sup> deletion

Kindly note that Monotard<sup>®</sup> (an insulin zinc suspension) and Ultratard<sup>®</sup> (a crystalline insulin zinc suspension) have been discontinued by Novo Nordisk since 1<sup>st</sup> January 2005.

Insulatard<sup>®</sup> (an isophane insulin suspension) will replace both products. The total daily insulin dosage may either remain unchanged or need minor adjusting when switching between these products.

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. As with all insulins, close glucose monitoring is recommended during the transfer and the initial weeks thereafter.

Should any difficulties arise when transferring to Insulatard<sup>®</sup>, Diabetes Clinic, St. Luke's Hospital should be contacted on 2595 1554..

The change-over is going to be carried out sequentially throughout the government dispensaries over the next three months to avoid wastage of the current stocks of Monotard<sup>®</sup> and Ultratard<sup>®</sup>.

For your attention, please

Dr Ray Busuttil  
Director General, Health